Teva Inks $100m+ Deal To Settle West Virginia Opioid Claims
Israeli Company ‘Continues To Actively Negotiate A National Settlement’
Executive Summary
Teva has struck a further cash-and-medicines settlement agreement to resolve opioid-related claims in the US. A bench trial had been due to start in West Virginia by the end of this month, where Teva is to pay $75m over 15 years plus generic Narcan.
You may also be interested in...
What’s Next? Five Things To Look Out For In July
This month, long-awaited new pricing measures in Canada will come into force, while several trials will either kick off or end, including a liability opioids case involving Teva in San Francisco and Hatch-Waxman litigation over Otsuka/Lundbeck’s Rexulti.
Teva: Payers Hold The Cards On Material 2023 Adalimumab Opportunity
Fresh from partner Alvotech resolving patent litigation in the US for its proposed Humira biosimilar, Teva management has detailed the firm’s expectations around the product and the crucial issue of supply.
Teva Settles Opioid Litigation In Florida For $177m
Teva has settled the opioid claims it faced in the state of Florida, alongside CVS, Allergan and Endo.